| Code | CSB-RA004936MB12HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to ILB-2101, designed to specifically target CD40, a costimulatory protein belonging to the tumor necrosis factor receptor superfamily. CD40 is expressed on antigen-presenting cells, including B cells, dendritic cells, and macrophages, where it plays a critical role in adaptive immune responses by facilitating T cell activation and antibody class switching. The CD40-CD40L interaction is essential for germinal center formation and immune memory development. Dysregulation of CD40 signaling has been implicated in various pathological conditions, including autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, as well as B cell malignancies and solid tumors.
ILB-2101 is an investigational agonistic anti-CD40 antibody that has been evaluated in preclinical and clinical studies for its potential to enhance anti-tumor immunity. This biosimilar provides researchers with a valuable tool for investigating CD40-mediated immune mechanisms, studying costimulatory pathway modulation, and exploring therapeutic strategies in oncology and immunology research settings.
There are currently no reviews for this product.